Pulmonary Hypertension Secondary to Left Heart Disease: Pathophysiology and Therapeutic Challenges
International Journal of Current Pharmaceutical Review and Research · 31.05.2026 · 18 (05)
DOI: 10.25258/ijcpr.18.5.135 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 31.05.2026. Verfasst von Pankaj Kumar und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Pulmonary hypertension secondary to left heart disease (PH-LHD; Group 2 PH) is the most frequent form of pulmonary hypertension and is associated with excess dyspnoea, right ventricular dysfunction, recurrent heart-failure admissions and therapeutic uncertainty.
Aim
To evaluate the clinical profile, pathophysiological phenotype, echocardiographic/hemodynamic severity and therapeutic challenges among patients with PH-LHD in a tertiary-care setting in Bihar, India.
Methods
This prospective observational study included 80 consecutive adults with suspected PH-LHD attending Government Medical College and Hospital, Purnea, from 10 April 2025 to 25 March 2026. Patients underwent structured clinical assessment, electrocardiography, chest radiography, transthoracic echocardiography, biochemical testing and optimisation of left-heart-disease-directed therapy. Right-heart catheterisation was performed when clinically indicated. PH-LHD was classified as isolated post-capillary pulmonary hypertension (Ipc-PH) or combined post- and pre-capillary pulmonary hypertension (Cpc-PH) according to contemporary hemodynamic principles. Outcomes included symptom improvement, six-minute walk distance (6MWD) improvement, pulmonary artery systolic pressure (PASP) reduction, heart-failure hospitalization and a composite poor outcome.
Results
Mean age was 58.9 ± 10.6 years; 45 patients (56.3%) were male. HFpEF was present in 37 (46.3%), HFrEF in 25 (31.3%) and significant valvular disease in 18 (22.5%). Cpc-PH was identified in 30 (37.5%) patients and was associated with higher PASP (64.9 ± 12.1 vs 51.8 ± 9.8 mmHg; p
Zitieren
APA
Kumar, P., & Prakash, P. (2026). Pulmonary Hypertension Secondary to Left Heart Disease: Pathophysiology and Therapeutic Challenges. International Journal of Current Pharmaceutical Review and Research, 18(05). https://doi.org/10.25258/ijcpr.18.5.135
Vancouver
Kumar P, Prakash P. Pulmonary Hypertension Secondary to Left Heart Disease: Pathophysiology and Therapeutic Challenges. International Journal of Current Pharmaceutical Review and Research. 2026;18(05). doi:10.25258/ijcpr.18.5.135
BibTeX
@article{Kumar2026,
author = {Kumar, Pankaj and Prakash, Prem},
title = {Pulmonary Hypertension Secondary to Left Heart Disease: Pathophysiology and Therapeutic Challenges},
journal = {International Journal of Current Pharmaceutical Review and Research},
year = {2026},
volume = {18},
number = {05},
doi = {10.25258/ijcpr.18.5.135}
}
EUVIMED